Core A: Protein Sciences
核心 A:蛋白质科学
基本信息
- 批准号:10425026
- 负责人:
- 金额:$ 95.84万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-09-02 至 2025-08-31
- 项目状态:未结题
- 来源:
- 关键词:Antigen-Antibody ComplexAntigensAreaB-LymphocytesBindingBiological AssayBioreactorsCell SeparationCollaborationsComplexCoronavirusCoronavirus spike proteinCryoelectron MicroscopyCyclic GMPDevelopmentDocumentationEnsureEpitopesEquipmentFab ImmunoglobulinsFormulationGlycoproteinsGoalsHIV-1Human ResourcesImaging TechniquesIn VitroInfluenzaInstitutesInstitutionLaboratoriesLeadMedicineMethodsMonoclonal AntibodiesPeptidesProcessProductionProtein EngineeringProtein SortingsProteinsPublic HealthQuality ControlReagentReference StandardsResearchResearch SupportResolutionSarbecovirusScienceScientistSerologySpeedStructureSystemTechnology TransferTestingTimeTranslatingTranslationsVaccine DesignVaccinesViralX-Ray Crystallographyanalytical methodbasebetacoronavirus vaccineclinical developmentcoronavirus vaccinecostdesignexperienceexperimental studyflexibilityhigh throughput screeningimmunogenicityin vivoindustry partnerinnovationiterative designmethod developmentnanoparticlepolyclonal antibodypreclinical developmentprogramsprotein structure functionreceptorscale upstructural biologyvaccine candidate
项目摘要
PROJECT SUMMARY – CORE A: PROTEIN SCIENCES
Core A (Protein Sciences) will provide essential support to our Projects and Cores in three areas: protein
production and characterization, high-resolution structure determination, and process development and
technology transfer. Core A’s protein production and characterization efforts, led by Dr. Neil King and Lauren
Carter, will leverage the extensive facilities and equipment at UW’s Institute for Protein Design (IPD) as well as
its unique expertise in nanoparticle immunogens. Rigorous characterization and quality control testing will ensure
the provision of high-quality antigens, nanoparticle immunogens, and protein-based reagents to support the
scientific efforts of Projects 1 (Veesler), 2 (King), and 3 (Pulendran). Structure determination by both X-ray
crystallography and cryo-electron microscopy will be led by Dr. David Veesler and will make use of state-of-the-
art, in-house facilities including UW’s Arnold and Mabel Beckman Cryo-EM Center. High-resolution structures of
designed antigens, nanoparticle immunogens, and antigen-antibody complexes will provide critical information
to guide the iterative design of stabilized antigens and broadly protective vaccines in Project 2. Process
development and technology transfer of our lead vaccine candidates (a pan-sarbecovirus vaccine at the end of
Year 2 and a pan-betacoronavirus vaccine at the end of Year 5), led by Dr. Neil King and Lauren Carter, will
build upon the IPD’s proven track record in translating innovative protein-based medicines and vaccines to
industry partners. A dedicated team at the IPD will develop the methods and documentation for a comprehensive
technology transfer package that will speed preclinical and clinical development of our broadly protective
coronavirus vaccines.
项目摘要--核心A:蛋白质科学
核心A(蛋白质科学)将在三个领域为我们的项目和核心提供必要的支持:蛋白质
生产和表征、高分辨率结构确定以及工艺开发和
技术转让。核心A的蛋白质生产和表征工作,由Neil King博士和Lauren领导
卡特将利用华盛顿大学蛋白质设计研究所(IPD)的广泛设施和设备,以及
其在纳米颗粒免疫原方面的独特专业知识。严格的表征和质量控制测试将确保
提供高质量的抗原、纳米颗粒免疫原和基于蛋白质的试剂以支持
项目1(Veesler)、项目2(King)和项目3(Pulendran)的科学努力。用两种X射线确定结构
结晶学和冷冻电子显微镜将由大卫·维斯勒博士领导,并将利用最新的-
艺术和内部设施,包括密歇根大学的阿诺德和梅布尔·贝克曼冷冻-EM中心。的高分辨率结构
设计的抗原、纳米颗粒免疫原和抗原-抗体复合体将提供关键信息
指导项目2中稳定抗原和广泛保护性疫苗的迭代设计。
我们的主要候选疫苗的开发和技术转让(#年末的泛肉瘤病毒疫苗
第二年和第五年年底的泛贝塔冠状病毒疫苗),由尼尔·金博士和劳伦·卡特领导,将
基于IPD在将以蛋白质为基础的创新药物和疫苗转化为
行业合作伙伴。IPD的一个专职团队将为全面的
技术转让套餐,将加快我们广泛保护的临床前和临床发展
冠状病毒疫苗。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Neil King其他文献
Neil King的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Neil King', 18)}}的其他基金
Project 2: Structure-based antigen and nanoparticle vaccine design
项目2:基于结构的抗原和纳米颗粒疫苗设计
- 批准号:
10425031 - 财政年份:2022
- 资助金额:
$ 95.84万 - 项目类别:
Structure-based design of broadly protective coronavirus vaccines
基于结构的广泛保护性冠状病毒疫苗的设计
- 批准号:
10425024 - 财政年份:2022
- 资助金额:
$ 95.84万 - 项目类别:
相似国自然基金
Neo-antigens暴露对肾移植术后体液性排斥反应的影响及其机制研究
- 批准号:2022J011295
- 批准年份:2022
- 资助金额:10.0 万元
- 项目类别:省市级项目
结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究
- 批准号:30801055
- 批准年份:2008
- 资助金额:19.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Bovine herpesvirus 4 as a vaccine platform for African swine fever virus antigens in pigs
牛疱疹病毒 4 作为猪非洲猪瘟病毒抗原的疫苗平台
- 批准号:
BB/Y006224/1 - 财政年份:2024
- 资助金额:
$ 95.84万 - 项目类别:
Research Grant
Uncovering tumor specific antigens and vulnerabilities in ETP-acute lymphoblastic leukemia
揭示 ETP-急性淋巴细胞白血病的肿瘤特异性抗原和脆弱性
- 批准号:
480030 - 财政年份:2023
- 资助金额:
$ 95.84万 - 项目类别:
Operating Grants
A novel vaccine approach combining mosquito salivary antigens and viral antigens to protect against Zika, chikungunya and other arboviral infections.
一种结合蚊子唾液抗原和病毒抗原的新型疫苗方法,可预防寨卡病毒、基孔肯雅热和其他虫媒病毒感染。
- 批准号:
10083718 - 财政年份:2023
- 资助金额:
$ 95.84万 - 项目类别:
Small Business Research Initiative
Regulation of B cell responses to vaccines by long-term retention of antigens in germinal centres
通过在生发中心长期保留抗原来调节 B 细胞对疫苗的反应
- 批准号:
MR/X009254/1 - 财政年份:2023
- 资助金额:
$ 95.84万 - 项目类别:
Research Grant
Adaptive Discrimination of Risk of Antigens in Immune Memory Dynamics
免疫记忆动态中抗原风险的适应性辨别
- 批准号:
22KJ1758 - 财政年份:2023
- 资助金额:
$ 95.84万 - 项目类别:
Grant-in-Aid for JSPS Fellows
22-ICRAD Call 2 - Improving the diagnosis of tuberculosis in domestic ruminants through the use of new antigens and test platforms
22-ICRAD 呼吁 2 - 通过使用新抗原和测试平台改善家养反刍动物结核病的诊断
- 批准号:
BB/Y000927/1 - 财政年份:2023
- 资助金额:
$ 95.84万 - 项目类别:
Research Grant
Protective immunity elicited by distinct polysaccharide antigens of classical and hypervirulent Klebsiella
经典和高毒力克雷伯氏菌的不同多糖抗原引发的保护性免疫
- 批准号:
10795212 - 财政年份:2023
- 资助金额:
$ 95.84万 - 项目类别:
Integrative proteome analysis to harness humoral immune response against tumor antigens
综合蛋白质组分析利用针对肿瘤抗原的体液免疫反应
- 批准号:
23K18249 - 财政年份:2023
- 资助金额:
$ 95.84万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
Functionally distinct human CD4 T cell responses to novel evolutionarily selected M. tuberculosis antigens
功能独特的人类 CD4 T 细胞对新型进化选择的结核分枝杆菌抗原的反应
- 批准号:
10735075 - 财政年份:2023
- 资助金额:
$ 95.84万 - 项目类别:
Targeting T3SA proteins as protective antigens against Yersinia
将 T3SA 蛋白作为针对耶尔森氏菌的保护性抗原
- 批准号:
10645989 - 财政年份:2023
- 资助金额:
$ 95.84万 - 项目类别: